Is Thyroid Cancer Recurrence Risk Increased After Transplantation?

Tisset, H.; Kamar, Nassim; Faugeron, Isabelle; Roy, Pascal; Pouteil‐Noble, Claire; Klein, Marc; Mourad, Georges; Drui, Delphine; Cao, Christine Do; Leenhardt, Laurence; Allix, Ingrid; Bonichon, F.; Morélon, Emmanuel; Leboulleux, Sophie; Kelly, A.; Niccoli, Patricia; Toubert, Marie‐Elisabeth; Frimat, Luc; Vantyghem, Marie-Christine; Bournaud, Claire; Schlumberger, Martin; Borson‐Chazot, Françoise

doi:10.1210/jc.2013-1357

Cited by 11 publications

(5 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To our knowledge, only three other studies have specifically investigated the occurrence and prognosis of thyroid cancer in relationship to solid organ transplantations . The most comprehensive study so far by Tisset et al included 68 patients with solid organ transplantation and thyroid cancer from 13 hospitals in France. Although they found a high rate of aggressive features, prognosis of thyroid cancer did not seem to be altered by transplantation, with a similar rate of recurrent disease compared to the general population.…”

Section: Discussionmentioning

confidence: 99%

“…Rates of thyroid cancer have also been shown to be increased among transplant patients, higher than that expected in the general population . The exact etiology behind this increased rate is unknown . Most likely immunosuppressive agents play an important role, though similar rates of thyroid cancer have been shown in patients with end stage renal failure not undergoing transplantation .…”

Section: Introductionmentioning

confidence: 99%

“…Since most evidence comes from national registries and multicenter studies, specific data with regards to presentation and prognosis is often lacking. Few studies have investigated the characteristics of post‐transplantation thyroid cancer and overall evidence is scarce . We therefore, performed the largest single‐center transplant study on this topic, to our knowledge, including a review of the literature to investigate (i) the rate of thyroid cancer in patients after solid organ transplantations; and (ii) the stage of presentation and prognosis of patients with thyroid cancer after solid organ transplant compared to the general population.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

De novo thyroid cancer following solid organ transplantation—A 25‐year experience at a high‐volume institution with a review of the literature

Kluijfhout

Drake

Pasternak

et al. 2017

Journal of Surgical Oncology

View full text Add to dashboard Cite

Rate of thyroid cancer is not significantly higher in patients who underwent solid organ transplantation compared to general population. Stage at presentation and prognosis also appear to be similar to that of the general population. Post-transplant screening for thyroid cancer remains debatable; however, when thyroid cancer is discovered, treatment should be similar to that of non-transplant patients. J. Surg. Oncol. 2017;115:105-108. © 2017 Wiley Periodicals, Inc.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

De novo thyroid cancer following solid organ transplantation—A 25‐year experience at a high‐volume institution with a review of the literature

Kluijfhout

Drake

Pasternak

et al. 2017

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…A third of the patients were asymptomatic when thyroid cancer was discovered and all but one of the 32 patients responded to standard treatment (thyroidectomy and iodine-131 therapy) [ 26 ]. Therefore, this higher incidence of thyroid cancer was not associated with a worse outcome after allo-HCST, as also demonstrated after transplantation even if the initial presentation was more aggressive [ 27 , 28 ].…”

Section: Endocrine Complicationsmentioning

confidence: 79%

Management of endocrino-metabolic dysfunctions after allogeneic hematopoietic stem cell transplantation

Vantyghem

Cornillon

Decanter³

et al. 2014

Orphanet J Rare Dis

Self Cite

View full text Add to dashboard Cite

Allogeneic hematopoietic stem cell transplantation is mainly indicated in bone marrow dysfunction related to blood diseases, but also in some rare diseases (adrenoleucodystrophy, mitochondrial neurogastrointestinal encephalomyopathy or MNGIE…). After decades, this treatment has proven to be efficient at the cost of numerous early and delayed side effects such as infection, graft-versus-host disease, cardiovascular complications and secondary malignancies. These complications are mainly related to the conditioning, which requires a powerful chemotherapy associated to total body irradiation (myelo-ablation) or immunosuppression (non myelo-ablation). Among side effects, the endocrine complications may be classified as 1) hormonal endocrine deficiencies (particularly gonado- and somatotropic) related to delayed consequences of chemo- and above all radiotherapy, with their consequences on growth, puberty, bone and fertility); 2) auto-immune diseases, particularly dysthyroidism; 3) secondary tumors involving either endocrine glands (thyroid carcinoma) or dependent on hormonal status (breast cancer, meningioma), favored by immune dysregulation and radiotherapy; 4) metabolic complications, especially steroid-induced diabetes and dyslipidemia with their increased cardio-vascular risk. These complications are intricate. Moreover, hormone replacement therapy can modulate the cardio-vascular or the tumoral risk of patients, already increased by radiotherapy and chemotherapy, especially steroids and anthracyclins… Therefore, patients and families should be informed of these side effects and of the importance of a long-term follow-up requiring a multidisciplinary approach.

show abstract

“…DTCs are mainly treated with a combination of surgery, thyroid-stimulating hormone suppression and radioactive iodine ( 131 I) therapy, resulting in a good prognosis. 3,4 Nevertheless, patients with DTC could have recurrence/persistent disease 5–9 and progress to poorly differentiated (PDTC) and anaplastic thyroid cancers (ATC). In addition, other rare forms of thyroid cancer, such as medullary thyroid cancer arising from para-follicular C cells and Hurthle cell carcinoma, present a more aggressive phenotype at the time of diagnosis and are typically associated with a poorer survival rate.…”

Section: Introductionmentioning

confidence: 99%

Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAFV600E or wild-type BRAF

Antonello

Nucera

2013

Oncogene

View full text Add to dashboard Cite

Molecular signature of advanced and metastatic thyroid carcinoma involves deregulation of multiple fundamental pathways activated in the tumor microenvironment. They include BRAFV600E and AKT that affect tumor initiation, progression and metastasis. Human thyroid cancer orthotopic mouse models are based on human cell lines that generally harbor genetic alterations found in human thyroid cancers. They can reproduce in vivo and in situ (into the thyroid) many features of aggressive and refractory human advanced thyroid carcinomas, including local invasion and metastasis. Humanized orthotopic mouse models seem to be ideal and commonly used for preclinical and translational studies of compounds and therapies not only because they may mimic key aspects of human diseases (e.g. metastasis), but also for their reproducibility. In addition, they might provide the possibility to evaluate systemic effects of treatments. So far, human thyroid cancer in vivo models were mainly used to test single compounds, non selective and selective. Despite the greater antitumor activity and lower toxicity obtained with different selective drugs in respect to non-selective ones, most of them are only able to delay disease progression, which ultimately could restart with similar aggressive behavior. Aggressive thyroid tumors (for example, anaplastic or poorly differentiated thyroid carcinoma) carry several complex genetic alterations that are likely cooperating to promote disease progression and might confer resistance to single-compound approaches. Orthotopic models of human thyroid cancer also hold the potential to be good models for testing novel combinatorial therapies. In this article, we will summarize results on preclinical testing of selective and nonselective single compounds in orthotopic mouse models based on validated human thyroid cancer cell lines harboring the BRAFV600E mutation or with wild-type BRAF. Furthermore, we will discuss the potential use of this model also for combinatorial approaches, which are expected to take place in the upcoming human thyroid cancer basic and clinical research.

show abstract

Is Thyroid Cancer Recurrence Risk Increased After Transplantation?

Abstract: The prognosis of thyroid cancer does not seem to be altered by transplantation. This suggests that a history of thyroid cancer should not be considered a contraindication.

Cited by 11 publications

References 41 publications

De novo thyroid cancer following solid organ transplantation—A 25‐year experience at a high‐volume institution with a review of the literature

De novo thyroid cancer following solid organ transplantation—A 25‐year experience at a high‐volume institution with a review of the literature

Management of endocrino-metabolic dysfunctions after allogeneic hematopoietic stem cell transplantation

Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAFV600E or wild-type BRAF

Contact Info

Product

Resources

About